Didronel PMO

etidronate disodium

Didronel, Didronel PMO (UK)

Pharmacologic class: Bisphosphonate

Therapeutic class: Bone resorption inhibitor, hypocalcemic agent

Pregnancy risk category B


Blocks calcium absorption, slowing bone metabolism and reducing bone resorption and formation


Tablets: 200 mg, 400 mg

Indications and dosages

Paget's disease

Adults: 5 to 10 mg/kg P.O. daily as a single dose for up to 6 months, or 11 to 20 mg/kg P.O. daily for up to 3 months

Heterotopic ossification after hip replacement

Adults: 20 mg/kg P.O. daily for 1 month before and 3 months after surgery

Heterotopic ossification in spinal cord injury

Adults: Initially, 20 mg/kg P.O. daily for 2 weeks, decreased to 10 mg/kg P.O. daily for 10 weeks

Dosage adjustment

• Decreased glomerular filtration rate


• Hypersensitivity to drug or its components
• Abnormalities of esophagus, such as stricture or achalasia, that delay esophageal emptying
• Osteomalacia


Use cautiously in:
• renal impairment, long bone fractures, active upper GI condition (such as Barrett's esophagus, dysphagia, other esophageal diseases, gastritis, duodenitis, or ulcers)
• pregnant or breastfeeding patients
• children (safety not established).


• Give with 6 to 8 oz of water 2 hours before first meal.
• Make sure patient doesn't eat for 2 hours after receiving dose.
• Know that therapy longer than 3 months is not recommended.

Adverse reactions

GI: nausea, constipation, stomatitis, diarrhea, esophageal irritation

Metabolic: hyperphosphatemia

Musculoskeletal: bone pain and tenderness, fractures, osteonecrosis of the jaw

Skin: rash


Drug-drug.Warfarin: increased prothrombin time

Drug-diagnostic tests.Serum phosphorus: increased level

Patient monitoring

• Monitor fluid intake and output.
• Monitor patient for GI discomfort. Divide doses as needed to ease symptoms.
• Assess bowel pattern. If constipation occurs, increase fluids and administer stool softeners, as prescribed.
• Closely monitor renal function tests and serum phosphorus level.

Patient teaching

• Instruct patient to take drug first thing in morning on an empty stomach, with 6 to 8 oz of water only and to stay upright for at least 30 minutes afterward.
• Instruct patient not to take drug with food because of decreased drug absorption.
• Tell patient not to consume highcalcium products, such as milk or antacids, or vitamins and mineral supplements high in calcium, iron, magnesium, or aluminum, within 2 hours of taking dose.

Tell patient to immediately discontinue drug and notify prescriber if severe chest pain, difficulty or painful swallowing, or new or worsening heartburn occurs.
• Advise patient to report bone pain or decreased range of motion.
• As appropriate, review all other significant adverse reactions and interactions, especially those related to the drugs and tests mentioned above.

Didronel PMO

References in periodicals archive ?
5000x 500mg paracetamol Tabs 50 x 250 mg Amoxycillin 100 x 5ml Amoxycillin 250 x 1500 Amoxycillin Caps BP 1500 x 200mg Ibuprofen Tabs BP 28 x 10mg istin Tabs 14 x 400mg Didronel pmo 76x 500 mg cacit calsum carbonat.
In non-hormonal therapies in the bone health area, P&G pioneered the development of bisphosphonate compounds such as Didronel PMO (oral etidronate intermittent cyclical therapy), which has rapidly become a leading bone health treatment in most of the 16 countries (outside the United States) where it is approved, and Risedronate, a third generation bisphosphonate now being studied in large Phase III clinical trials.
Didronel PMO, P&G's drug for treating and preventing post-menopausal osteoporosis, is a market leader in many of the 14 countries where it's available.